KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Average (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Equity Average for 15 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 88.47% to $8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, down 88.47% year-over-year, with the annual reading at $46.3 million for FY2025, 50.18% down from the prior year.
  • Equity Average hit $8.2 million in Q4 2025 for Inovio Pharmaceuticals, down from $10.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $545.1 million in Q2 2021 to a low of $8.2 million in Q4 2025.
  • Historically, Equity Average has averaged $217.9 million across 5 years, with a median of $169.0 million in 2023.
  • Biggest five-year swings in Equity Average: soared 439.56% in 2021 and later tumbled 88.47% in 2025.
  • Year by year, Equity Average stood at $426.6 million in 2021, then tumbled by 42.68% to $244.5 million in 2022, then crashed by 47.76% to $127.8 million in 2023, then tumbled by 44.41% to $71.0 million in 2024, then crashed by 88.47% to $8.2 million in 2025.
  • Business Quant data shows Equity Average for INO at $8.2 million in Q4 2025, $10.4 million in Q3 2025, and $39.9 million in Q2 2025.